Mecobalamin plus anti-VEGF injections for retinal vein occlusion with macular edema

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, outcome‑blinded, placebo‑controlled Phase 4 trial enrolling 120 treatment‑naive RVO patients at the First Affiliated Hospital of Chongqing Medical University. Participants are randomized 1:1 to receive standard anti‑VEGF intravitreal injections with either mecobalamin or placebo. Key outcomes include changes in best‑corrected visual acuity and retinal thickness measured by OCT, with scheduled follow‑up visits to monitor response and safety. The trial targets both vascular leakage and neural protection by combining anti‑VEGF therapy with a neurotrophic agent.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Diagnosis of RVO meeting the international diagnostic criteria 4,12, age 18-80 years, gender not limited Treatment-naive RVO-ME (no prior anti-VEGF, glucocorticoid, or laser therapy) The CST is confirmed to be ≥300μm by OCT The baseline BCVA (ETDRS letter count) was 20/400 to 20/40 (34-78 letters) Signed informed consent and ability to comply with follow-up.

Exclusion Criteria:

Combined with other eye diseases that cause ME (such as diabetic retinopathy, uveitis) Media opacities affecting imaging (such as severe cataract, vitreous hemorrhage) Prior anti-VEGF, steroid, or macular laser therapy Systemic use of glucocorticoids or immunosuppressants within 3 months Uncontrolled systemic disease (hypertension, diabetes, hepatic/renal dysfunction); pregnant or lactating women Allergy to mecobalamin or conbercept Unable to cooperate with examinations or follow-up, or participate in other clinical trials within one year

Where it's running

• No. 1, Friendship Road, Yuanjiagang, Yuzhong District, Chongqing City
  Chongqing, China Recruiting

Study contacts

• Study coordinator: Wen-Li Deng, doctoral
• Email: dengwenli@hospital.cqmu.edu.cn
• Phone: +8619823579019

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Robotic-assisted tPA injection for retinal vein occlusion

  This trial tests whether robot-assisted delivery of a clot-dissolving drug (tPA) into a blocked retinal vein can restore blood flow in people with central retinal vein occlusion.

  Recruiting University of Oxford · Oxford, Oxfordshire · NCT07820761

• ANXV (Annexin A5) infusions for non-proliferative diabetic retinopathy and retinal vein occlusion

  This will test whether short daily infusions of ANXV can be given safely and help improve vision or reduce the need for rescue medication in adults with recent-onset non-proliferative diabetic retinopathy or retinal vein occlusion.

  Recruiting Phase 2 Annexin Pharmaceuticals AB · London · NCT07259928

• Watching a short video before anti-VEGF eye injections

  This trial will test whether watching a brief procedural video before a first anti-VEGF intravitreal injection helps people with retinal diseases feel less anxious and have fewer or smaller subconjunctival hemorrhages.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07002372

• Using advanced imaging to analyze retinal vascular diseases

  This study is testing new imaging techniques to see how they can help doctors understand and track the progress of retinal diseases like diabetic retinopathy in both healthy people and those affected by these conditions.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT04505618

• MB-102 versus fluorescein sodium for retinal angiography imaging

  This trial will test whether the new dye MB-102 produces safe, high-quality retinal angiography images in adults with healthy eyes or retinal vascular disease compared with standard fluorescein sodium.

  Recruiting Early Phase 1 MediBeacon · Ann Arbor, Michigan · NCT04008121

• Measuring sCD160 in eye fluids and blood to look for links with ischemic retinal diseases

  This project tests whether sCD160 levels in the eye and blood are linked to ischemic retinal disease in adults having eye surgery.

  Recruiting CHU de Reims · Reims · NCT03680794

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.